The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals' drug to treat a rare hormonal disorder on Thursday, ...
Paltusotine (Palsonify; Crinetics), a novel nonpeptide somatostatin receptor type 2 nonpeptide (SST2) agonist, was approved by the FDA for the treatment of acromegaly in adults who had an inadequate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback